217 related articles for article (PubMed ID: 25337550)
1. Epigenetic therapies as a promising strategy for overcoming chemoresistance in epithelial ovarian cancer.
Suh DH; Kim MK; Kim HS; Chung HH; Song YS
J Cancer Prev; 2013 Sep; 18(3):227-34. PubMed ID: 25337550
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review.
Smith HJ; Straughn JM; Buchsbaum DJ; Arend RC
Gynecol Oncol Rep; 2017 May; 20():81-86. PubMed ID: 28378010
[TBL] [Abstract][Full Text] [Related]
3. Metabolic approaches to overcoming chemoresistance in ovarian cancer.
Suh DH; Kim MK; No JH; Chung HH; Song YS
Ann N Y Acad Sci; 2011 Jul; 1229():53-60. PubMed ID: 21793839
[TBL] [Abstract][Full Text] [Related]
4. The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer.
Tayama S; Motohara T; Narantuya D; Li C; Fujimoto K; Sakaguchi I; Tashiro H; Saya H; Nagano O; Katabuchi H
Oncotarget; 2017 Jul; 8(27):44312-44325. PubMed ID: 28574829
[TBL] [Abstract][Full Text] [Related]
5. Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism.
Li SS; Ma J; Wong AST
J Gynecol Oncol; 2018 Mar; 29(2):e32. PubMed ID: 29468856
[TBL] [Abstract][Full Text] [Related]
6. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
7. Novel targeted therapies in epithelial ovarian cancer: from basic research to the clinic.
Gadducci A; Cosio S; Genazzani AR
Expert Rev Endocrinol Metab; 2007 Mar; 2(2):225-238. PubMed ID: 30754175
[TBL] [Abstract][Full Text] [Related]
8. New strategy for overcoming resistance to chemotherapy of ovarian cancer.
Kigawa J
Yonago Acta Med; 2013 Jun; 56(2):43-50. PubMed ID: 24031151
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer.
Liu MX; Siu MK; Liu SS; Yam JW; Ngan HY; Chan DW
Oncotarget; 2014 Feb; 5(4):944-58. PubMed ID: 24659709
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.
Matei DE; Nephew KP
Gynecol Oncol; 2010 Feb; 116(2):195-201. PubMed ID: 19854495
[TBL] [Abstract][Full Text] [Related]
11. Signaling within the epithelial ovarian cancer tumor microenvironment: the challenge of tumor heterogeneity.
Horowitz M; Esakov E; Rose P; Reizes O
Ann Transl Med; 2020 Jul; 8(14):905. PubMed ID: 32793749
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms and Therapeutic Targets of microRNA-associated Chemoresistance in Epithelial Ovarian Cancer.
Zhang L; Nadeem L; Connor K; Xu G
Curr Cancer Drug Targets; 2016; 16(5):429-41. PubMed ID: 27040353
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action.
Itamochi H
World J Biol Chem; 2010 Jul; 1(7):209-20. PubMed ID: 21537476
[TBL] [Abstract][Full Text] [Related]
14. Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?
Walters Haygood CL; Arend RC; Straughn JM; Buchsbaum DJ
World J Stem Cells; 2014 Sep; 6(4):441-7. PubMed ID: 25258665
[TBL] [Abstract][Full Text] [Related]
15. Over-expression of Sirt1 contributes to chemoresistance and indicates poor prognosis in serous epithelial ovarian cancer (EOC).
Shuang T; Wang M; Zhou Y; Shi C
Med Oncol; 2015 Dec; 32(12):260. PubMed ID: 26520143
[TBL] [Abstract][Full Text] [Related]
16. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
17. The emerging roles of E3 ubiquitin ligases in ovarian cancer chemoresistance.
Meng Y; Qiu L; Zhang S; Han J
Cancer Drug Resist; 2021; 4(2):365-381. PubMed ID: 35582023
[TBL] [Abstract][Full Text] [Related]
18. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer.
Li M; Balch C; Montgomery JS; Jeong M; Chung JH; Yan P; Huang TH; Kim S; Nephew KP
BMC Med Genomics; 2009 Jun; 2():34. PubMed ID: 19505326
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of ITGBL1 predicts poor prognosis and promotes chemoresistance in ovarian cancer.
Song J; Yang P; Lu J
Cancer Biomark; 2020; 27(1):51-61. PubMed ID: 31683459
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
